We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
+11.29%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$244M
AUM Growth
+$29.9M
(+14%)
Cap. Flow
+$3.97M
Cap. Flow
% of AUM
1.63%
Top 10 Holdings %
Top 10 Hldgs %
46.31%
Holding
79
New
4
Increased
21
Reduced
24
Closed
3
Top Buys
| 1 |
argenx
ARGX
|
+$3.4M |
| 2 |
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
|
+$2.69M |
| 3 |
BLUE
bluebird bio
BLUE
|
+$2.63M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$2.06M |
| 5 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$1.85M |
Top Sells
| 1 |
DexCom
DXCM
|
+$2.23M |
| 2 |
Minerva Neurosciences
NERV
|
+$977K |
| 3 |
LMNX
Luminex Corp
LMNX
|
+$945K |
| 4 |
Larimar Therapeutics
LRMR
|
+$784K |
| 5 |
AtriCure
ATRC
|
+$684K |
Sector Composition
| 1 | Healthcare | 88.76% |
| 2 | Financials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
| $29M | 11.9% |
169,675
+11,000
| +7% | +$1.85M |
|
2
Stereotaxis
STXS
$162M
| $16.6M | 6.8% |
13,680,554
| – | – |
|
|
SAGE
3
DELISTED
Sage Therapeutics
SAGE
| $14M | 5.76% |
99,306
+3,306
| +3% | +$510K |
|
|
4
AtriCure
ATRC
$1.76B
| $10.3M | 4.23% |
293,729
-21,616
| -7% | -$684K |
|
|
NXTM
5
DELISTED
NxStage Medical Inc.
NXTM
| $8.54M | 3.51% |
306,119
| – | – |
|
|
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
| $8.17M | 3.36% |
132,770
+1,000
| +0.8% | +$64.3K |
|
|
BPMC
7
DELISTED
Blueprint Medicines
BPMC
| $7.24M | 2.97% |
92,691
| – | – |
|
|
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
| $6.86M | 2.82% |
138,264
+40,500
| +41% | +$2.06M |
|
|
ALDR
9
DELISTED
Alder Biopharmaceuticals
ALDR
| $6.59M | 2.71% |
396,013
| – | – |
|
10
Akebia Therapeutics
AKBA
$370M
| $5.53M | 2.27% |
625,738
+15,000
| +2% | +$134K |
|
11
Ascendis Pharma A/S
ASND
$17.4B
| $5.47M | 2.25% |
77,242
+3,497
| +5% | +$241K |
|
|
12
DexCom
DXCM
$28.6B
| $5.29M | 2.17% |
148,000
-72,000
| -33% | -$2.23M |
|
13
Neurocrine Biosciences
NBIX
$17.2B
| $5.04M | 2.07% |
41,008
-4,500
| -10% | -$511K |
|
14
ProQR Therapeutics
PRQR
$243M
| $5.04M | 2.07% |
260,336
+88,985
| +52% | +$946K |
|
15
BioCryst Pharmaceuticals
BCRX
$2.4B
| $4.97M | 2.04% |
652,086
+47,434
| +8% | +$319K |
|
|
16
argenx
ARGX
$54B
| $4.88M | 2% |
64,300
+38,351
| +148% | +$3.4M |
|
|
FOMX
17
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $4.63M | 1.9% |
808,000
+470,000
| +139% | +$2.69M |
|
|
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.54M | 1.86% |
98,547
+3,305
| +3% | +$134K |
|
|
LKFT
19
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
| $4.45M | 1.83% |
39,609
-1,000
| -2% | -$106K |
|
20
Kura Oncology
KURA
$998M
| $4.21M | 1.73% |
240,500
+1,000
| +0.4% | +$19.2K |
|
|
LMNX
21
DELISTED
Luminex Corp
LMNX
| $4.2M | 1.72% |
138,391
-31,500
| -19% | -$945K |
|
|
IMMU
22
DELISTED
Immunomedics Inc
IMMU
| $3.71M | 1.52% |
178,000
-5,000
| -3% | -$118K |
|
|
CBAY
23
DELISTED
Cymabay Therapeutics
CBAY
| $3.26M | 1.34% |
294,511
| – | – |
|
24
iShares Biotechnology ETF
IBB
$9.2B
| $3.18M | 1.31% |
26,100
| – | – |
|
25
Xenon Pharmaceuticals
XENE
$6.52B
| $3.14M | 1.29% |
237,683
-56,679
| -19% | -$657K |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML